The efficacy of selinexor (KPT-330), an XPO1 inhibitor, on non-hematologic cancers : a comprehensive review
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature..
PURPOSE: Selinexor is a novel XPO1 inhibitor which inhibits the export of tumor suppressor proteins and oncoprotein mRNAs, leading to cell-cycle arrest and apoptosis in cancer cells. While selinexor is currently FDA approved to treat multiple myeloma, compelling preclinical and early clinical studies reveal selinexor's efficacy in treating hematologic and non-hematologic malignancies, including sarcoma, gastric, bladder, prostate, breast, ovarian, skin, lung, and brain cancers. Current reviews of selinexor primarily highlight its use in hematologic malignancies; however, this review seeks to summarize the recent evidence of selinexor treatment in solid tumors.
METHODS: Pertinent literature searches in PubMed and the Karyopharm Therapeutics website for selinexor and non-hematologic malignancies preclinical and clinical trials.
RESULTS: This review provides evidence that selinexor is a promising agent used alone or in combination with other anticancer medications in non-hematologic malignancies.
CONCLUSION: Further clinical investigation of selinexor treatment for solid malignancies is warranted.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:149 |
|---|---|
| Enthalten in: |
Journal of cancer research and clinical oncology - 149(2023), 5 vom: 08. Mai, Seite 2139-2155 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Landes, Jennifer R [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
31TZ62FO8F |
|---|
| Anmerkungen: |
Date Completed 14.04.2023 Date Revised 14.04.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s00432-022-04247-z |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM344606511 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM344606511 | ||
| 003 | DE-627 | ||
| 005 | 20231226023149.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s00432-022-04247-z |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1148.xml |
| 035 | |a (DE-627)NLM344606511 | ||
| 035 | |a (NLM)35941226 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Landes, Jennifer R |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The efficacy of selinexor (KPT-330), an XPO1 inhibitor, on non-hematologic cancers |b a comprehensive review |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 14.04.2023 | ||
| 500 | |a Date Revised 14.04.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. | ||
| 520 | |a PURPOSE: Selinexor is a novel XPO1 inhibitor which inhibits the export of tumor suppressor proteins and oncoprotein mRNAs, leading to cell-cycle arrest and apoptosis in cancer cells. While selinexor is currently FDA approved to treat multiple myeloma, compelling preclinical and early clinical studies reveal selinexor's efficacy in treating hematologic and non-hematologic malignancies, including sarcoma, gastric, bladder, prostate, breast, ovarian, skin, lung, and brain cancers. Current reviews of selinexor primarily highlight its use in hematologic malignancies; however, this review seeks to summarize the recent evidence of selinexor treatment in solid tumors | ||
| 520 | |a METHODS: Pertinent literature searches in PubMed and the Karyopharm Therapeutics website for selinexor and non-hematologic malignancies preclinical and clinical trials | ||
| 520 | |a RESULTS: This review provides evidence that selinexor is a promising agent used alone or in combination with other anticancer medications in non-hematologic malignancies | ||
| 520 | |a CONCLUSION: Further clinical investigation of selinexor treatment for solid malignancies is warranted | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a KPT-330 | |
| 650 | 4 | |a Non-hematologic cancer | |
| 650 | 4 | |a SINE compounds | |
| 650 | 4 | |a Selinexor | |
| 650 | 4 | |a Solid malignancy | |
| 650 | 7 | |a selinexor |2 NLM | |
| 650 | 7 | |a 31TZ62FO8F |2 NLM | |
| 650 | 7 | |a Karyopherins |2 NLM | |
| 650 | 7 | |a Antineoplastic Agents |2 NLM | |
| 650 | 7 | |a Triazoles |2 NLM | |
| 650 | 7 | |a Hydrazines |2 NLM | |
| 700 | 1 | |a Moore, Stephen A |e verfasserin |4 aut | |
| 700 | 1 | |a Bartley, Brooke R |e verfasserin |4 aut | |
| 700 | 1 | |a Doan, Hung Q |e verfasserin |4 aut | |
| 700 | 1 | |a Rady, Peter L |e verfasserin |4 aut | |
| 700 | 1 | |a Tyring, Stephen K |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of cancer research and clinical oncology |d 1981 |g 149(2023), 5 vom: 08. Mai, Seite 2139-2155 |w (DE-627)NLM000394610 |x 1432-1335 |7 nnns |
| 773 | 1 | 8 | |g volume:149 |g year:2023 |g number:5 |g day:08 |g month:05 |g pages:2139-2155 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s00432-022-04247-z |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 149 |j 2023 |e 5 |b 08 |c 05 |h 2139-2155 | ||